MHR FUND MANAGEMENT LLC 13D and 13G filings for Iovance Biotherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-09 5:40 pm Purchase | 2023-12-31 | 13G | Iovance Biotherapeutics, Inc. IOVA | MHR FUND MANAGEMENT LLC | 20,083,951 7.800% | 8,000,000 (+66.20%) | Filing |
| 2022-12-30 4:12 pm Purchase | 2022-12-22 | 13G | Iovance Biotherapeutics, Inc. IOVA | MHR FUND MANAGEMENT LLC | 12,083,951 6.700% | 12,083,951 (New Position) | Filing |